- Home
- OTLK
as 12-27-2024 4:00pm EST
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | ISELIN |
| Market Cap: | 33.6M | IPO Year: | 2016 |
| Target Price: | $28.68 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.87 - $12.85 | Next Earning Date: | 02-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Outlook Therapeutics Inc. News
OTLK Breaking Stock News: Dive into OTLK Ticker-Specific Updates for Smart Investing
MT Newswires
14 hours ago
Outlook Therapeutics' Annual Loss Per Share Narrows in FY24; Shares Up
GlobeNewswire
16 hours ago
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
MT Newswires
14 days ago
Outlook Therapeutics to Cut 23% Workforce to Lower Costs
GlobeNewswire
14 days ago
Outlook Therapeutics® Streamlines Operations
GlobeNewswire
24 days ago
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
GlobeNewswire
24 days ago
Outlook Therapeutics® Announces Executive Leadership Transition
MT Newswires
a month ago
Chardan Downgrades Outlook Therapeutics to Neutral From Buy, Puts Price Target 'Under Review' After $53 Price Target
TipRanks
a month ago
Outlook Therapeutics price target lowered to $9 from $50 at BTIG
Compare OTLK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OTLK Outlook Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.